EQS-Adhoc: Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
vom 16.07.2021, 07:00 Uhr
Bild: pixabay.com
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
16-Jul-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex
Lonza Group AG / Key word(s): Agreement/Development of Sales
16-Jul-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza s Ibex
(R) Solutions, providing customers with fast, flexible and tailor-made solutions